BioCentury | Dec 4, 2020
Finance

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

...has a machine-learning platform to map age-related molecular pathways, plans to begin clinical trials of HIF-PH...
...2024. Investors included Kiwoom Investment, NH Investment & Securities, Aju IB Investment and Widwin Investment.   TARGETSHIF-PH (EGLN...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

...III PRO2TECT program, which evaluated the oral HIF-PH...
...LSE:AZN; NYSE:AZN) market roxadustat in China.TARGETSHIF-PHHypoxia-inducible factor prolyl hydroxylase Paul...
...roxadustat (ASP1517, FG-4592) Akebia Therapeutics Inc. FibroGen Inc. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN...
BioCentury | Jul 21, 2020
Product Development

Data Bytes: COVID-19 pipeline still growing

...to the clinic are a pair of candidates aimed at decreasing lung damage: the oral HIF-PH...
BioCentury | Jun 30, 2020
Regulation

Data Bytes: Drug approvals in Japan

...of which are products from Novartis AG (NYSE:NVS; SIX:NOVN). Two of the approvals are for HIF-PH...
...only other approval for the mAb against IL-6R is in Canada. Targets HIF-PH (EGLN) - Hypoxia-inducible factor prolyl hydroxylase...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

...anemia due to chronic kidney disease. The company plans to seek approval of the oral HIF-PH...
...were not disclosed. Targets GNRH (GNRH1) - Gonadotropin releasing hormone 1 Target2 HIF-PH (EGLN) - Hypoxia-inducible factor prolyl hydroxylase...
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

...It now expects top-line data in 2022 from a Phase III CV outcomes study of HIF-PH...
...as YE20. Partners FibroGen Inc. (NASDAQ:FGEN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) market the most advanced HIF-PH...
...constant exchange rates. Adjusted EPS for 2019 was 123.9p, up 1%. Targets HIF-PH (EGLN) - Hypoxia-inducible factor prolyl hydroxylase...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...for roxadustat to treat anemia caused by chronic kidney disease. It is the only approved HIF-PH...
...conductance regulator HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 HIF-PH (EGLN) - Hypoxia-inducible factor prolyl hydroxylase...
BioCentury | Dec 24, 2019
Company News

Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

...to FDA for Evrenzo roxadustat to treat anemia associated with chronic kidney disease. The first-in-class HIF-PH...
...circulate blood through an artificial lung. Targets: CGRP - Calcitonin gene-related peptide; HIF-PH (EGLN) - Hypoxia-inducible factor prolyl hydroxylase...
...FG-4592) BioMarin Pharmaceutical Inc. Allergan plc Eisai Co. Ltd. ViiV Healthcare Ltd. FibroGen Inc. Factor VIII Calcitonin gene-related peptide (CGRP) receptor Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Vero...
BioCentury | Oct 8, 2019
Tools & Techniques

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

...transcription factors, HIF1A and ARNT. Their discoveries include HIF1A modification by prolyl hydroxylases, such as EGLN...
...for Cell Engineering. Targets: ARNT (HIF1β) - Aryl hydrocarbon receptor nuclear translocator; EGLN (HIF-PH) - Hypoxia-inducible factor prolyl hydroxylase...
...Oxford Francis Crick Institute Johns Hopkins University Dana-Farber Cancer Institute Harvard Medical School Hypoxia-inducible factor 1 alpha (HIF1A) (HIF1-alpha) Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) von...
BioCentury | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to treat major depressive disorder, and granted approval to HIF-PH...
...and Taiwan. Targets: GITR (TNFRSF18) - Glucocorticoid-induced tumor necrosis factor receptor-related protein; HIF-PH (EGLN) - Hypoxia-inducible factor prolyl hydroxylase BioCentury...
Items per page:
1 - 10 of 150